Format

Send to

Choose Destination
J Neuroimmunol. 2018 Dec 15;325:61-63. doi: 10.1016/j.jneuroim.2018.10.006. Epub 2018 Oct 19.

Antinuclear antibodies in Frontotemporal Dementia: the tip's of autoimmunity iceberg?

Author information

1
Rheumatology and Clinical Immunology, Spedali Civili Hospital, Brescia, Italy.
2
Neurology Unit, Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. Electronic address: antoalberici@yahoo.it.
3
Neurology Unit, Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
4
Rheumatology and Clinical Immunology, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
5
III Laboratory of Analyses, Spedali Civili Hospital, Brescia, Italy.
6
Neurology Unit, Spedali Civili Hospital, Brescia, Italy.
7
Department of Molecular Pathology, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy.
8
Rheumatology and Clinical Immunology, Spedali Civili Hospital, Brescia, Italy; Rheumatology and Clinical Immunology, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Abstract

Recent studies suggest a role of the autoimmune system dysregulation in Frontotemporal dementia (FTD). In the present study, we performed a broad immunological screening in a large sample of sporadic FTD patients. We reported a significant increase of antinuclear autoantibodies (ANA) positivity in 100 FTD patients as compared to 100 healthy controls (HC) (60% vs. 13%, p < .001). In FTD, ANA-positive and ANA-negative patients did not differ for any clinical feature. These data extend and further confirm autoimmune dysregulation in FTD. However, it still remains to be clarified whether these antibodies have a potential pathogenic role or represent simply an epiphenomenon.

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center